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Previewspotential regulation of pathological mye-
lopoiesis by one of the members of the
nuclear receptor superfamily and sug-
gests that RORC1 could be a key driver
of the differentiation of MDSCs and TAM
(Figure 1).REFERENCES
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Molecular studies of intra-tumor heterogeneity (ITH) are revealing a large amount of DNA-based variation
in many individual tumors. In a recent publication by Yates and colleagues, the ITH of breast tumors was
examined and shown to have important implications for the development of resistant disease, metastasis,
and clinical sequencing efforts.Human breast cancer shows great
inter-tumor diversity in every feature that
one might examine, including histology,
response to therapy, and patient survival
times. At the same time, there is a long
history of evidence for significant intra-
tumor heterogeneity (ITH), which can itself
be manifested in histological differences,
cellular differences, and molecular differ-
ences. In fact, studies on ITH as assessed
at the DNA level have been documented
and studied for decades (Kallioniemi,
1988). The new study by Yates et al.
(2015) masterfully brings these ITH
DNA-based analyses into the 21st cen-
tury, providing an unprecedented look at
the sub-clonal composition of individual
breast tumors.
The first question addressed by the au-
thors was the amount of spatial ITH seen
within individual untreated primary tumors
through in-depth analysis of 12 patients
in which each tumor was sampled from
8 different locations. Each location wasthen subjected to deep sequencing using
360 and 454 gene panels. Two thirds
(i.e., 8 of 12) of the tumors showed clear
somatic mutation heterogeneity across
the different isolates from a single tumor;
2 of 12 showed copy number ITH; and 2
of 12 showed little genetic variation.
Thus, the majority of tumors showed mo-
lecular ITH, and, in most tumors, this was
spatially segregated. This characteriza-
tion of spatial ITH supports the findings
of others (Ding et al., 2010; Shah et al.,
2012), but with a larger number of breast
tumors. Finally, the authors highlight 4
of 12 cases in which the sub-clonal
mutations included important genes like
TP53, PIK3CA, and BRCA2. This finding
dictates the necessity to sequence at
high-depth in the clinical setting to
generate sensitive and specific sub-
clonal mutation calls.
The finding that oncogenic mutations
can be sub-clonal prompts the question
of whether these were present at diag-nosis or if they occurred later during tumor
evolution. Previous work in breast cancer
has shown that, within triple-negative
breast cancer (TNBC), TP53 mutations
are frequent and tend to be early events
(Ding et al., 2010; Shah et al., 2012). Yates
et al. (2015) extend this work using four
patients that presented with multi-focal
disease (i.e., two to five foci per patient).
In each case, foci were clearly genetically
related to the others within a patient but
also had many private mutations that
were present at high variant allele frac-
tions (VAF). The authors infer that individ-
ual foci must have arisen from a common
ancestor, and thus their spatial separation
was almost akin to local metastasis. Sec-
ond, each foci must have undergone
a ‘‘clonal sweep’’, evident by numerous
private mutations with high VAF. These
results are in line with those of other re-
searchers (Navin et al., 2011; Nik-Zainal
et al., 2012), supporting the concept of
‘‘clonal sweep’’ in breast cancer. Another, August 10, 2015 ª2015 Elsevier Inc. 149
Cancer Cell
Previewsresult of this work was some evidence
that groups of genetic variants are pre-
sent in the metastasis at high VAF and in
the primary tumor at low VAF, similar to
what was recently described in prostate
(Gundem et al., 2015). Further work is
needed to understand if metastatic sites
are typically seeded from a single clone
or a more heterogeneous population of
cells.
Yates et al. (2015) also touched
briefly on comparisons of primary tumors
versus residual disease after neoadjuvant
chemotherapy. In 5 of 18 cases, they
found evidence for the emergence of
sub-clones not originally detected before
chemotherapy. The notion of tumor evolu-
tion (through continual acquisition of new
mutations or punctuated clonal expan-
sion) will be important to understand for
clinical studies. At the least, these results
strongly argue that diagnostic specimens
for DNA-based assays should sample the
tumor as close to the time of the new treat-
ment as possible. Otherwise, it is plausible
that there are differences in the residual
disease or metastatic site that do not
represent the earlier diagnostic specimen.
In suchcases, test resultsmay lead tosub-
optimal therapeutic decisions.
The authors also hypothesized that a
quantitative measure of ITH, based upon
somatic DNA variation, might have clinical
implications, and thus they developed an
‘‘index of heterogeneity’’. No associations
with estrogen receptor (ER) status, grade,
lymphocyte infiltration, tumor Ki-67 score,
or response to chemotherapy were
observed across the complete cohort.
The finding of no association between
the index of heterogeneity and clinical
features may be evidence that clonal di-
versity itself is not meaningful. However,
the lack of association may be due to
limited power due to the small sample
size (n = 50) and diverse composition of
the cohort (27 ER+, 3 HER2+, and 20
TNBC). Regardless, assessments of ITH
are of clear biological value, and we
believe (like Yates and colleagues) that
measures of ITH will ultimately aid our
understanding and treatment of cancers.
Molecular assessments of ITH are now
in the translation period from the research
setting into the clinical setting, with the
ultimate question regarding their clinical150 Cancer Cell 28, August 10, 2015 ª2015 Eutility. For common clinical use, an
assay must achieve analytical validation
and clinical validation and ultimately
demonstrate clinical utility. Measurement
of ITH, and future trials with ITH, will
need to be developed in all three areas.
In terms of analytical validity, sequencing
depths and computational protocols for
reconstructing clonal structure are still
being developed and will need to be opti-
mized. In terms of clinical validity, recent
work has shown that exome-based mea-
surement of ITH may predict outcomes
in head and neck cancer (Mroz et al.,
2015), and it seems intuitive that tumors
with greater ITH would harbor more ge-
netic diversity from which drug resistant
sub-clones could emerge.
Lastly, the clinical utility of ITH as a
biomarker has yet to be demonstrated,
and it is on this front where the unan-
swered questions are the most clinically
challenging. These questions include the
prognostic potential of ITH, while biologi-
cally plausible and with good prelimi-
nary evidence, must be weighed against
numerous well-developed prognostic
biomarkers. Second is the question of
what to do with a ‘‘clinically actionable’’
variant when it is sub-clonal. For
example, a case where standard practice
sequencing of a lung adenocarcinoma
identifies a sub-clonal (i.e., 15% VAF)
EGFR L858R mutation. Should the EGFR
tyrosine kinase inhibitor (TKI) inhibitor be
given even when the majority of the
tumor cells do not contain the mutation?
The breast cancer ASCO/CAP guidelines
state that sub-clonal (i.e., not present
within all tumor cells) HER2 high pro-
tein expression and/or amplification or
ER protein expression indicates treat-
ment with anti-HER2 and anti-estrogens
agents, respectively (Hammond et al.,
2010; Wolff et al., 2007). Such indications
are dictated by trial criteria, and in this
context, it appears that the community is
in agreement that targeted agents should
be considered in sub-clonal disease.
A more difficult question arises when
sub-clonal resistance mutations are iden-
tified. For example, consider the case of a
lung cancer at diagnosis with a L858R
EGFR mutation with high VAF and a sub-
clonal T790M resistance mutation (i.e.,
1%–5% VAF). This situation is observedlsevier Inc.in the clinic and poses the very difficult
question of whether to prescribe the stan-
dard of care (i.e., first-generation EGFR
TKIs) or to jump to the drugs that target
the T790M and L858R EGFR mutation
variants. These are already challenges
being faced in lung cancer and chronic
myeloid leukemia with drugs targeting
BCR-ABL. The study by Yates and col-
leagues contributes to these efforts by
providing a new and powerful means of
assessing ITH and a means of assessing
tumor branching evaluation. Their find-
ings impact clinical study design in breast
cancer and could soon impact clinical
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